Core Insights - Veracyte, Inc. (VCYT) is set to report its fourth-quarter 2025 results on February 25, with expectations of strong performance based on previous earnings surprises [1][9] Financial Performance - The Zacks Consensus Estimate for revenues is $138.7 million, indicating a 16.9% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is 41 cents, reflecting a 13.9% year-over-year growth [2] - Earnings estimates have increased by 2.5% in the last 30 days, suggesting positive sentiment leading up to the earnings report [3] Business Segments - The core testing business is anticipated to show solid revenue growth, driven by strong volumes in Decipher and Afirma tests [4][9] - Decipher Prostate tests delivered approximately 26,700 tests in the third quarter, marking 14 consecutive quarters of over 25% year-over-year volume growth, a trend expected to continue [5] - Test volumes in the high-risk localized segment are also expected to have increased, supported by ongoing research and clinical adoption [6] Product Insights - Product volume in the third quarter was around 2,200 tests, with a year-over-year revenue growth of 4%, a trend expected to persist [7] - However, management has indicated a decline in product gross margin due to a transition to a contract manufacturing model [7][9] Market Position - VCYT has an Earnings ESP of +7.98% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating earnings estimates [11] - The company is facing challenges in its biopharma revenues and expects lower product gross margins in the fourth quarter due to restructuring efforts [9][10]

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities reported modest gains in the fourth quarter of 2025. The quarter started as a continuation of the post-Liberation Day risk-on market environment, while it ended on a strong note, driven by a positive macroeconomic backdrop. Attractive valuations, earnings recovery, broadening of the market, and a shift from mega-ca ...

Group 1: Dividend Announcement - GE HealthCare Technologies Inc. declared a cash dividend of $0.035 per share for Q1 2026, to be disbursed on May 15, 2026, to shareholders of record as of April 3, 2026, with the amount unchanged since Q4 2025 [1] Group 2: Product Launch - GE HealthCare launched ReadyFix, a remote fleet management solution for healthcare systems, on February 9, designed to monitor and support uptime for connected medical devices [2] - ReadyFix collects real-time device data for remote diagnostics, repair, proactive maintenance, and performance optimization, allowing biomedical engineering teams to deploy standardized clinical configurations and schedule software updates remotely [2][3] Group 3: Operational Efficiency - The ReadyFix solution aims to reduce device disruptions and downtime, thereby maintaining continuity of cardiac care through consistent performance of ECG workstations [3] - The management highlighted the launch's timeliness due to the increasing complexity in hospital device fleets, where biomedical teams manage numerous connected devices and face operational strain from maintenance workloads [4] Group 4: Company Overview - GE HealthCare Technologies Inc. designs, develops, and manufactures medical technology, pharmaceutical diagnostics, and digital solutions, including diagnostic imaging systems, ultrasound devices, patient monitoring equipment, imaging agents, and healthcare IT platforms [5]

Core Insights - The Middle East's healthcare infrastructure is transitioning from merely building hospitals to optimizing their operations, with Becton, Dickinson and Company (BD) playing a pivotal role in this evolution [2][3] - BD has restructured to focus solely on medical technologies, separating its biosciences and diagnostics businesses to enhance its Connected Care segment [3][4] Company Strategy - BD's priorities include advancing infusion management systems, enhancing pharmacy automation, and expanding patient monitoring solutions, aiming to create a cohesive ecosystem [4][6] - The company is redefining its engagement with healthcare providers by fostering long-term collaborations that align with hospitals' strategic goals [5][6] Technological Innovations - BD is developing a connected ecosystem that integrates medication management, infusion therapy, and patient monitoring, which is expected to improve clinical workflows [7][8] - The integration of these systems allows for real-time alignment of therapy delivery with patient responses, enhancing clinical decision-making [10][11] AI and Data Utilization - BD's approach to AI is grounded in its proximity to therapy pathways, allowing for the development of algorithms that are clinically relevant [12][13] - The company emphasizes the importance of data governance and security, particularly in regions with strict regulations, ensuring patient data remains protected [15][16] Market Growth and Trends - Growth in healthcare is anticipated to be driven by the expansion of Connected Care deployments and partnerships with hospitals focused on system-level integration [17][19] - The nature of growth is evolving, with hospitals needing to justify investments through clear evidence of clinical and operational returns [20][21] Future Outlook - The future of healthcare for BD is closely tied to the maturation of Connected Care, which aims to create an integrated framework for therapy delivery and monitoring [23][24] - The healthcare delivery model is shifting towards continuous, data-informed management, necessitating cohesive communication between therapy and monitoring systems [25][26]

Core Insights - Heartflow, Inc. will release its financial results for Q4 and the full year of 2025 on March 18, 2026, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), transforming it from a leading cause of death into a manageable condition through early detection and accurate diagnosis [4] - The Heartflow One platform utilizes AI to create personalized 3D models from coronary CTA images, providing actionable insights into plaque characteristics and their impact on blood flow without invasive procedures [4] Technology and Research - Heartflow's technology is supported by the world's largest coronary imaging dataset, with over 160 million annotated CTA images, enabling advanced AI models that deliver accurate insights across diverse patient populations [6] - The company's AI-driven solutions have been validated in over 200 studies involving more than 365,000 patients, achieving coronary CTA image acceptance rates exceeding 97% [6] - Heartflow's solutions are integrated into clinical workflows, providing quality-reviewed analyses instantly upon order, facilitating timely decision-making for clinicians [6] Market Presence - Heartflow has been adopted by more than 1,400 institutions globally, enhancing its commercial presence and making its solutions accessible to a diverse patient population [3]

Core Viewpoint - Edwards Lifesciences Corporation will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026, with CFO Scott Ullem scheduled to present [1] Company Information - The presentation by Scott Ullem is set for 10:15 a.m. ET [1] - A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website, with an archived version accessible later the same day [1]

Core Viewpoint - The article discusses the performance of ASX companies, highlighting significant movements in stock prices and investor interest, particularly focusing on CSL Ltd, Pro Medicus, and BMG Resources as key players in the market this week [2][3]. Company Summaries CSL Ltd - CSL Ltd has experienced a significant decline, with a -15.9% drop in value for the week, contributing to a -40% year-to-date performance [3]. - The company's current market value is approximately $74 billion, with shares trading around $152.53, down from a previous high of over $300 per share [4]. Pro Medicus - Pro Medicus has also faced challenges, with shares dropping nearly -30% during the week, currently priced at $123 per share [5]. - The company has signed over A$280 million in new contracts, leading to a five-year contracted revenue of around A$1.1 billion, although there are concerns about execution in the second half of the year [7]. BMG Resources - BMG Resources, a gold and lithium exploration company, has initiated a major 10,000-meter diamond drilling campaign at its Abercromby project, aiming to increase its existing resource of 518Koz [8]. - The company has reported a +116% year-to-date increase in share price, currently trading at 3.5 cents [9].

Core Insights - Baxter International Inc. shares experienced a 15% decline intra-day following the release of fourth-quarter earnings that fell short of expectations and a weaker-than-anticipated guidance for 2026 [1] Financial Performance - The company reported adjusted EPS of $0.44, which was below analyst estimates of $0.54 [2] - Revenue reached $2.97 billion, surpassing the consensus estimate of $2.84 billion, marking an 8% increase on a reported basis and a 3% operational growth compared to the previous year [2] - Despite the revenue exceeding expectations, concerns regarding profitability negatively impacted investor sentiment [2] Future Guidance - Baxter projected fiscal 2026 adjusted EPS to be in the range of $1.85 to $2.05, significantly lower than the analyst consensus of $2.25 [2] Operational Challenges - President and CEO Andrew Hider acknowledged that while sales growth was achieved across all segments, the fourth-quarter performance did not meet internal expectations, highlighting the company's focus on operational improvements [3] - The company reported a U.S. GAAP net loss from continuing operations of $2.01 per diluted share, which included a $485 million goodwill impairment charge related to its Front Line Care reporting unit and a $330 million valuation allowance on U.S. deferred tax assets [3] Segment Performance - Medical Products & Therapies revenue increased by 6% to $1.39 billion [4] - Healthcare Systems & Technologies revenue rose by 5% to $827 million [4] - Pharmaceuticals revenue grew by 4% to $668 million [4]

Core Insights - Tian Ruixiang Holdings Limited is expanding its AI-powered healthcare ecosystem, solidifying its leadership in the Asia-Pacific region [1][5] - The company is entering strategic partnerships and acquisition discussions with Singapore's top three medical technology leaders to enhance insurance-clinic integration and precision diagnostics [1][2] Strategic Partnership and Acquisitions - The proposed collaborations and acquisitions are expected to be finalized within the next 12 months, integrating Singapore's AI diagnostic expertise into TIRX's pan-Asia network [2][5] - This integration aims to create a fully integrated AI healthcare platform, enhancing precision, accessibility, and efficiency for patients, providers, and insurers [2][5] Transformative Pillars - **AI Diagnostic Supremacy**: The partnership will leverage Singaporean medical tech leaders' AI platforms to achieve over 95% accuracy in predictive diagnostics within TIRX's insurance clinic networks, improving early disease detection and treatment outcomes [3][4] - **Pan-Asia Integration**: Establishing a seamless network of insurance clinics across the Asia-Pacific, enabling real-time patient data integration and personalized treatment pathways [4] - **Operational Excellence**: Automating 70% of routine healthcare workflows, reducing operational costs by over 40%, and unlocking significant value across the healthcare value chain [4] Market Position and Growth Potential - The completion of the acquisitions and partnerships is subject to regulatory approvals and shareholder consent, with TIRX aiming to finalize these within the next 12 months [5] - This strategic move positions TIRX as a dominant player in the Asia-Pacific AI healthcare market, potentially catalyzing exponential growth in AI-related revenue [5][6]

NBA legend Muggsy Bogues joins effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow AnalysisMOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to inc ...